These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 18195093)

  • 21. Natalizumab.
    Berger JR
    Drugs Today (Barc); 2006 Oct; 42(10):639-55. PubMed ID: 17136224
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale.
    Rice GP; Hartung HP; Calabresi PA
    Neurology; 2005 Apr; 64(8):1336-42. PubMed ID: 15851719
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The discovery of natalizumab, a potent therapeutic for multiple sclerosis.
    Steinman L
    J Cell Biol; 2012 Oct; 199(3):413-6. PubMed ID: 23109666
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Natalizumab therapy for highly active pediatric multiple sclerosis.
    Kornek B; Aboul-Enein F; Rostasy K; Milos RI; Steiner I; Penzien J; Hellwig K; Pitarokoili K; Storm van's Gravesande K; Karenfort M; Blaschek A; Meyer A; Seidl R; Debelic D; Vass K; Prayer D; Kristoferitsch W; Bayas A
    JAMA Neurol; 2013 Apr; 70(4):469-75. PubMed ID: 23420110
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The alpha4beta1 and alpha5beta1 integrins mediate engraftment of granulocyte-colony-stimulating factor-mobilized human hematopoietic progenitor cells.
    Carstanjen D; Gross A; Kosova N; Fichtner I; Salama A
    Transfusion; 2005 Jul; 45(7):1192-200. PubMed ID: 15987366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of anti-CD52 antibody alemtuzumab on ex-vivo culture of umbilical cord blood stem cells.
    Lim CK; Sun L; Feng Q; Law P; Chua WT; Lim SN; Hwang WY
    J Hematol Oncol; 2008 Oct; 1():19. PubMed ID: 18947412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
    Rudick RA; Sandrock A
    Expert Rev Neurother; 2004 Jul; 4(4):571-80. PubMed ID: 15853576
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the anti-HIV activity of natalizumab, an antibody against integrin alpha4.
    Pauls E; Ballana E; Moncunill G; Bofill M; Clotet B; Ramo-Tello C; Esté JA
    AIDS; 2009 Jan; 23(2):266-8. PubMed ID: 19112691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel treatment options for inflammatory bowel disease: targeting alpha 4 integrin.
    Lanzarotto F; Carpani M; Chaudhary R; Ghosh S
    Drugs; 2006; 66(9):1179-89. PubMed ID: 16827596
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Natalizumab: Perspectives from the Bench to Bedside.
    Shirani A; Stüve O
    Cold Spring Harb Perspect Med; 2018 Dec; 8(12):. PubMed ID: 29500304
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of the adhesion molecules CD49d and CD49e on G-CSF-mobilized CD34+ cells of patients with solid tumors or non-Hodgkin's and Hodgkin's lymphoma and of healthy donors is inversely correlated with the amount of mobilized CD34+ cells.
    Zeller W; Kröger N; Berger J; Krueger W; Dierlamm J; Stockschläder M; Gutensohn K; Hossfeld DK; Zander AR
    J Hematother Stem Cell Res; 1999 Oct; 8(5):539-46. PubMed ID: 10791904
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natalizumab: a new therapy for acute ischemic stroke?
    Simats A; García-Berrocoso T; Montaner J
    Expert Rev Neurother; 2016 Sep; 16(9):1013-21. PubMed ID: 27476862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab.
    Frohman EM; Monaco MC; Remington G; Ryschkewitsch C; Jensen PN; Johnson K; Perkins M; Liebner J; Greenberg B; Monson N; Frohman TC; Douek D; Major EO
    JAMA Neurol; 2014 May; 71(5):596-602. PubMed ID: 24664166
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment.
    Castellazzi M; Delbue S; Elia F; Gastaldi M; Franciotta D; Rizzo R; Bellini T; Bergamaschi R; Granieri E; Fainardi E
    Dis Markers; 2015; 2015():901312. PubMed ID: 26101453
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Natalizumab: AN 100226, anti-4alpha integrin monoclonal antibody.
    Drugs R D; 2004; 5(2):102-7. PubMed ID: 15293871
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Contribution of alpha6 integrins to hematopoietic stem and progenitor cell homing to bone marrow and collaboration with alpha4 integrins.
    Qian H; Tryggvason K; Jacobsen SE; Ekblom M
    Blood; 2006 May; 107(9):3503-10. PubMed ID: 16439681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Natalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosis.
    O'Connor P
    Expert Opin Biol Ther; 2007 Jan; 7(1):123-36. PubMed ID: 17150024
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multilineage engraftment in NOD/LtSz-scid/scid mice from mobilized human CD34+ peripheral blood progenitor cells.
    Hogan CJ; Shpall EJ; McNiece I; Keller G
    Biol Blood Marrow Transplant; 1997 Nov; 3(5):236-46. PubMed ID: 9450918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Melanoma complicating treatment with natalizumab for multiple sclerosis.
    Mullen JT; Vartanian TK; Atkins MB
    N Engl J Med; 2008 Feb; 358(6):647-8. PubMed ID: 18256405
    [No Abstract]   [Full Text] [Related]  

  • 40. A single T cell epitope drives the neutralizing anti-drug antibody response to natalizumab in multiple sclerosis patients.
    Cassotta A; Mikol V; Bertrand T; Pouzieux S; Le Parc J; Ferrari P; Dumas J; Auer M; Deisenhammer F; Gastaldi M; Franciotta D; Silacci-Fregni C; Fernandez Rodriguez B; Giacchetto-Sasselli I; Foglierini M; Jarrossay D; Geiger R; Sallusto F; Lanzavecchia A; Piccoli L
    Nat Med; 2019 Sep; 25(9):1402-1407. PubMed ID: 31501610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.